ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources; 
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles. 

Embargoed until May 26, 4:00 p.m. ET:

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan (JCO: Original Report) 
Rebecca Heist, et al. 

Improving Outcomes in High-Risk Myelodysplasia: Festina Lente (JCO: Editorial) 
Charles Craddock, et al.

Embargoed until May 25, 4:00 p.m. ET:

Long-Lasting Increased Risk of Human Papillomavirus–Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study (JCO: Original Report) 
Renee Ebisch, et al.

Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma (JCO: Original Report) 
Adam Olszewski, et al.

Ethics and Oncofertility: A Call for Religious Sensitivity (JOP: Original Contribution) 
Michele Hanselin, et al.

Embargoed until May 24, 4:00 p.m. ET:

Perspectives of Patients With Cancer on the Ethics of Rapid-Learning Health Systems (JCO: Original Report) 
Reshma Jagsi, et al.

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer (JCO: Original Report) 
Russell Petty, et al.

How Should We Choose the Best Therapy for Elderly Patients With Stage III Non–Small-Cell Lung Cancer? (JCO: Editorial) 
Wilfried Eberhardt, et al.

Embargoed until May 23, 4:00 p.m. ET:

Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group (JCO: Original Report) 
Naomi Winick, et al.

Design Challenges of an Episode-Based Payment Model in Oncology: The Centers for Medicare & Medicaid Services Oncology Care Model (JOP: Original Contribution)
Ronald Kline, et al. 

Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas (JCO PO: Original Report) 
Neerav Shukla, et al.

Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer (JCO CCI: Original Report) 
Sarah S Mougalian, et al.

Embargoed until May 22, 4:00 p.m. ET:

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy (JCO: Original Report) 
Jop Teepen, et al.

Embargoed until May 19, 4:00 p.m. ET:

Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (JCO: Original Report) 
German Ott, et al.

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy (JCO: Editorial) 
Jean-Luc Harousseau, et al.

Embargoed until May 18, 4:00 p.m. ET:

KIR3DL1 HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation (JCO: Original Report) 
Katharine Hsu, et al.

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1Rearrangement (JCO: Original Report) 
Byoung Chul Cho, et al.
(Editorial by Alice Shaw, et al.)

Expanding the Roster of ROS1 Inhibitors (JCO: Editorial) 
Alice Shaw, et al.
(Accompanies Byoung Chul Cho, et al.)

Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis (JCO PO: Original Report) 
Vamsidhar Velcheti, et al.

Embargo Information

The embargo date and time of a journal article coincides with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year, and may affect broader ASCO media privileges as well.  Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.